PharmaCorp Rx（PCRX）株式概要PharmaCorp Rx Inc.はカナダでPharmaChoiceの名称で小売薬局を運営している。 詳細PCRX ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長2/6過去の実績0/6財務の健全性4/6配当金0/6報酬当社が推定した公正価値より66.6%で取引されている 収益は年間48.11%増加すると予測されています アナリストらは、株価が34.7%上昇するだろうとほぼ一致している。 リスク分析過去5年間で収益は年間29.9%減少しました。 過去1年間で株主の希薄化は大幅に進んだ 意味のある時価総額がありません ( CA$101M )すべてのリスクチェックを見るPCRX Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW501,009 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG501,009 investors already sharing narrativesYour Fair ValueCA$Current PriceCA$0.49421.1% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-2m172m2016201920222025202620282031Revenue CA$171.6mEarnings CA$5.2mAdvancedSet Fair ValueView all narrativesPharmaCorp Rx Inc. 競合他社Grey Wolf HealthSymbol: TSXV:WOLFMarket cap: CA$61.4mTelyRx HoldingsSymbol: TSX:TELYMarket cap: CA$116.3mCareRxSymbol: TSX:CRRXMarket cap: CA$224.6mSucroSymbol: TSXV:SUGRMarket cap: CA$234.7m価格と性能株価の高値、安値、推移の概要PharmaCorp Rx過去の株価現在の株価CA$0.4952週高値CA$0.5852週安値CA$0.40ベータ-4.271ヶ月の変化3.13%3ヶ月変化17.86%1年変化1.02%3年間の変化n/a5年間の変化n/aIPOからの変化312.50%最新ニュースお知らせ • 3hPharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Eight PharmaChoice Canada bannered pharmacies in Eastern Canada from two unnamed vendor groups for approximately CAD 24.2 million.PharmaCorp Rx Inc. (TSXV:PCRX) entered into definitive share purchase agreement to acquire Eight PharmaChoice Canada bannered pharmacies in Eastern Canada from two unnamed vendor groups for approximately CAD 24.2 million on April 28, 2026. A cash consideration of CAD 24.2 million will be paid by PharmaCorp Rx Inc. subject to customary adjustments. As part of consideration, CAD 24.2 million is paid towards interests of Eight PharmaChoice Canada bannered pharmacies in Eastern Canada. The consideration is expected to be funded using the Corporation’s existing cash resources. In addition, the Corporation has also entered into non-binding letters of intent (“LOIs”) in respect of four additional pharmacy acquisitions. All locations will continue to be operated by their existing managing pharmacists, ensuring continuity of care, preserving patient relationships, and supporting a seamless transition and integration into the PharmaCorp platform. The transaction is subject to customary closing conditions. The Transaction is expected to close within 60 days. PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Eight PharmaChoice Canada bannered pharmacies in Eastern Canada from two unnamed vendor groups for approximately CAD 24.2 million on July 6, 2026.Reported Earnings • May 05Full year 2025 earnings released: CA$0.012 loss per share (vs CA$0.012 loss in FY 2024)Full year 2025 results: CA$0.012 loss per share (in line with FY 2024). Revenue: CA$20.9m (up 261% from FY 2024). Net loss: CA$1.48m (loss widened 46% from FY 2024). Revenue is forecast to grow 61% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Consumer Retailing industry in Canada. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.Reported Earnings • Nov 30Third quarter 2025 earnings released: CA$0.004 loss per share (vs CA$0.009 loss in 3Q 2024)Third quarter 2025 results: CA$0.004 loss per share (improved from CA$0.009 loss in 3Q 2024). Revenue: CA$4.80m (up 335% from 3Q 2024). Net loss: CA$427.5k (loss narrowed 56% from 3Q 2024).お知らせ • Nov 29PharmaCorp Rx Inc. Announces Management ChangesPharma Corp. Rx Inc. announced an executive transition in which Paul Dale has been appointed President and Chief Operating Officer, effective December 1, 2025, as Calvin LeRoux steps aside from the President role and assumes a one-year appointment as Strategic Advisor to the Chief Executive Officer. Mr. Dale has served as PharmaCorp’s Chief Operating Officer since its inception and will now take on broader leadership responsibilities as PharmaCorp advances its national expansion strategy. Mr. LeRoux will conclude his term as President on November 30, 2025. In his new advisory role, he will assist with the transition of responsibilities, contribute to strategic initiatives, and continue providing guidance on matters relating to PharmaChoice Canada. The company also pleased to announce that Sophia Sigler will join the Corporation as Director, Business Development, effective December 1, 2025. Ms. Sigler will lead the PharmaCorp’s business development initiatives, including sourcing acquisition opportunities, managing the transaction pipeline, coordinating due diligence, and supporting pharmacist partners through co-ownership and succession structures.New Risk • Nov 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 35% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CA$66.8m market cap, or US$47.5m).Buy Or Sell Opportunity • Nov 21Now 24% overvaluedOver the last 90 days, the stock has fallen 10% to CA$0.43. The fair value is estimated to be CA$0.35, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 156% over the last 3 years. Earnings per share has grown by 43%.最新情報をもっと見るRecent updatesお知らせ • 3hPharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Eight PharmaChoice Canada bannered pharmacies in Eastern Canada from two unnamed vendor groups for approximately CAD 24.2 million.PharmaCorp Rx Inc. (TSXV:PCRX) entered into definitive share purchase agreement to acquire Eight PharmaChoice Canada bannered pharmacies in Eastern Canada from two unnamed vendor groups for approximately CAD 24.2 million on April 28, 2026. A cash consideration of CAD 24.2 million will be paid by PharmaCorp Rx Inc. subject to customary adjustments. As part of consideration, CAD 24.2 million is paid towards interests of Eight PharmaChoice Canada bannered pharmacies in Eastern Canada. The consideration is expected to be funded using the Corporation’s existing cash resources. In addition, the Corporation has also entered into non-binding letters of intent (“LOIs”) in respect of four additional pharmacy acquisitions. All locations will continue to be operated by their existing managing pharmacists, ensuring continuity of care, preserving patient relationships, and supporting a seamless transition and integration into the PharmaCorp platform. The transaction is subject to customary closing conditions. The Transaction is expected to close within 60 days. PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Eight PharmaChoice Canada bannered pharmacies in Eastern Canada from two unnamed vendor groups for approximately CAD 24.2 million on July 6, 2026.Reported Earnings • May 05Full year 2025 earnings released: CA$0.012 loss per share (vs CA$0.012 loss in FY 2024)Full year 2025 results: CA$0.012 loss per share (in line with FY 2024). Revenue: CA$20.9m (up 261% from FY 2024). Net loss: CA$1.48m (loss widened 46% from FY 2024). Revenue is forecast to grow 61% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Consumer Retailing industry in Canada. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.Reported Earnings • Nov 30Third quarter 2025 earnings released: CA$0.004 loss per share (vs CA$0.009 loss in 3Q 2024)Third quarter 2025 results: CA$0.004 loss per share (improved from CA$0.009 loss in 3Q 2024). Revenue: CA$4.80m (up 335% from 3Q 2024). Net loss: CA$427.5k (loss narrowed 56% from 3Q 2024).お知らせ • Nov 29PharmaCorp Rx Inc. Announces Management ChangesPharma Corp. Rx Inc. announced an executive transition in which Paul Dale has been appointed President and Chief Operating Officer, effective December 1, 2025, as Calvin LeRoux steps aside from the President role and assumes a one-year appointment as Strategic Advisor to the Chief Executive Officer. Mr. Dale has served as PharmaCorp’s Chief Operating Officer since its inception and will now take on broader leadership responsibilities as PharmaCorp advances its national expansion strategy. Mr. LeRoux will conclude his term as President on November 30, 2025. In his new advisory role, he will assist with the transition of responsibilities, contribute to strategic initiatives, and continue providing guidance on matters relating to PharmaChoice Canada. The company also pleased to announce that Sophia Sigler will join the Corporation as Director, Business Development, effective December 1, 2025. Ms. Sigler will lead the PharmaCorp’s business development initiatives, including sourcing acquisition opportunities, managing the transaction pipeline, coordinating due diligence, and supporting pharmacist partners through co-ownership and succession structures.New Risk • Nov 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 35% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CA$66.8m market cap, or US$47.5m).Buy Or Sell Opportunity • Nov 21Now 24% overvaluedOver the last 90 days, the stock has fallen 10% to CA$0.43. The fair value is estimated to be CA$0.35, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 156% over the last 3 years. Earnings per share has grown by 43%.Recent Insider Transactions • Nov 16Executive Chairperson recently bought CA$1.0m worth of stockOn the 12th of November, Alan Simpson bought around 2m shares on-market at roughly CA$0.42 per share. This transaction amounted to 32% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Alan's only on-market trade for the last 12 months.お知らせ • Nov 13PharmaCorp Rx Inc. has completed a Composite Units Offering in the amount of CAD 23.0391 million.PharmaCorp Rx Inc. has completed a Composite Units Offering in the amount of CAD 23.0391 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 47,700,000 Price\Range: CAD 0.42 Discount Per Security: CAD 0.0252お知らせ • Aug 25PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2025PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2025.Reported Earnings • Aug 18Second quarter 2025 earnings released: CA$0.003 loss per share (vs CA$0.011 loss in 2Q 2024)Second quarter 2025 results: CA$0.003 loss per share (improved from CA$0.011 loss in 2Q 2024). Revenue: CA$4.40m (up CA$4.10m from 2Q 2024). Net loss: CA$384.1k (loss narrowed 36% from 2Q 2024).お知らせ • Aug 08PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business from PharmaChoice Canada Inc.PharmaCorp Rx Inc. (TSXV:PCRX) entered into share purchase agreement to acquire Pharmacy business from PharmaChoice Canada Inc. for CAD 2.4 million on June 24, 2025. The purchase price is subject to customary adjustments which will be paid using cash on hand. The Acquisition is expected to close on or about July 31, 2025, subject to satisfaction of customary closing conditions. PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business from PharmaChoice Canada Inc on August 7, 2025.Buy Or Sell Opportunity • Jul 30Now 24% overvaluedOver the last 90 days, the stock has fallen 4.1% to CA$0.47. The fair value is estimated to be CA$0.38, however this is not to be taken as a sell recommendation but rather should be used as a guide only.分析記事 • Jul 28Calculating The Fair Value Of PharmaCorp Rx Inc. (CVE:PCRX)Key Insights PharmaCorp Rx's estimated fair value is CA$0.38 based on 2 Stage Free Cash Flow to Equity With CA$0.46...Buy Or Sell Opportunity • Jul 08Now 29% overvalued after recent price riseOver the last 90 days, the stock has risen 2.1% to CA$0.49. The fair value is estimated to be CA$0.38, however this is not to be taken as a sell recommendation but rather should be used as a guide only.Buy Or Sell Opportunity • Jun 04Now 24% overvaluedOver the last 90 days, the stock has fallen 9.8% to CA$0.46. The fair value is estimated to be CA$0.37, however this is not to be taken as a sell recommendation but rather should be used as a guide only.New Risk • Feb 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (478% increase in shares outstanding). Revenue is less than US$1m (CA$1.4m revenue, or US$981k). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (CA$64.5m market cap, or US$45.3m).Board Change • Oct 04High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Ken Brownell was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 03PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business including land and buildings located in Atlanfic Canada.PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire Pharmacy business including land and buildings located in Atlanfic Canada for CAD 15.4 million on September 24, 2024. A cash consideration of CAD 15.18 million will be paid by PharmaCorp Rx Inc. The consideration consists of common equity of PharmaCorp Rx Inc. having a value of CAD 0.2 million to be issued for assets of Pharmacy business including land and buildings located in Atlanfic Canada. As part of consideration, CAD 15.38 million is paid towards assets of Pharmacy business including land and buildings located in Atlanfic Canada. For the period ending April 30, 2024, Pharmacy business including land and buildings located in Atlanfic Canada reported total revenue of CAD 10.36 million, net income of CAD 0.44 million, net assets of CAD 2.21 million and total debt of CAD 1.01 million. The transaction is subject to satisfaction of customary closing conditions, including the conditional acceptance of the TSX Venture Exchange. The expected completion of the transaction is October 1, 2024. PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business including land and buildings located in Atlanfic Canada on October 2, 2024.お知らせ • Sep 05PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of 90% stake in Pharmacy Located in Western Canada.PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire 90% stake in Pharmacy Located in Western Canada for CAD 2.2 million on August 22, 2024. The consideration will be funded from cash. A key aspect of the transaction is that the Vendors will retain a 10% interest in the Acquired Pharmacy and have agreed to continue working at the Acquired Pharmacy, with one of the Vendors entering into a long-term employment agreement as the managing pharmacist. The transaction is subject to satisfaction of customary closing conditions. The expected completion of the transaction is August 30, 2024. PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of 90% stake in Pharmacy Located in Western Canada on September 3, 2024.お知らせ • Aug 23PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire 90% stake in Pharmacy Located in Western Canada for CAD 2.2 million.PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire 90% stake in Pharmacy Located in Western Canada for CAD 2.2 million on August 22, 2024. The consideration will be funded from cash. A key aspect of the transacfion is that the Vendors will retain a 10% interest in the Acquired Pharmacy, and have agreed to confinue working at the Acquired Pharmacy, with one of the Vendors entering into a long-term employment agreement as the managing pharmacist. The transaction is subject to satisfaction of customary closing conditions. The expected completion of the transaction is August 30, 2024.お知らせ • Aug 22PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2024PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2024.New Risk • Aug 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 366% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Shareholders have been substantially diluted in the past year (366% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (CA$43.8m market cap, or US$31.6m).Board Change • Jul 23High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Director Glenn Fradette is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jun 08+ 1 more updateProton Capital Corp. has completed a Follow-on Equity Offering in the amount of CAD 20.797658 million.Proton Capital Corp. has completed a Follow-on Equity Offering in the amount of CAD 20.797658 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 51,994,146 Price\Range: CAD 0.4お知らせ • May 29Proton Capital Corp. (TSXV:PTN.P) agreed to acquire 75%stake in Saskatoon Family Pharmacy.Proton Capital Corp. (TSXV:PTN.P) agreed to acquire 75%stake in Saskatoon Family Pharmacy on May 27, 2024.お知らせ • Nov 17Proton Capital Corp., Annual General Meeting, Jan 22, 2024Proton Capital Corp., Annual General Meeting, Jan 22, 2024.株主還元PCRXCA Consumer RetailingCA 市場7D-1.0%-2.6%1.1%1Y1.0%12.3%29.6%株主還元を見る業界別リターン: PCRX過去 1 年間で12.3 % の収益を上げたCanadian Consumer Retailing業界を下回りました。リターン対市場: PCRXは、過去 1 年間で29.6 % のリターンを上げたCanadian市場を下回りました。価格変動Is PCRX's price volatile compared to industry and market?PCRX volatilityPCRX Average Weekly Movement10.0%Consumer Retailing Industry Average Movement4.2%Market Average Movement9.6%10% most volatile stocks in CA Market16.8%10% least volatile stocks in CA Market3.7%安定した株価: PCRX 、 Canadian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: PCRXの 週次ボラティリティ ( 10% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト20215Grady Brownwww.pharmacorprx.caファーマコープRx社は、カナダでファーマチョイスの名称で小売薬局を運営している。医療用医薬品とカスタム調合専門サービス、健康とウェルネス製品を含む減量とライフスタイル管理ソリューション、利便性と菓子製品を提供している。同社は2021年に法人化され、カナダのサスカトゥーンを拠点としている。もっと見るPharmaCorp Rx Inc. 基礎のまとめPharmaCorp Rx の収益と売上を時価総額と比較するとどうか。PCRX 基礎統計学時価総額CA$100.97m収益（TTM）-CA$1.62m売上高(TTM)CA$24.08m3.6xP/Sレシオ-53.4xPER（株価収益率PCRX は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計PCRX 損益計算書（TTM）収益CA$24.08m売上原価CA$14.61m売上総利益CA$9.47mその他の費用CA$11.08m収益-CA$1.62m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.0093グロス・マージン39.32%純利益率-6.71%有利子負債／自己資本比率6.6%PCRX の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/07 00:59終値2026/07/07 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PharmaCorp Rx Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Nick CorcoranAcumen Capital Finance Partners LimitedTania Armstrong-WhitworthCanaccord GenuityFred GataliRaymond James Ltd.
お知らせ • 3hPharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Eight PharmaChoice Canada bannered pharmacies in Eastern Canada from two unnamed vendor groups for approximately CAD 24.2 million.PharmaCorp Rx Inc. (TSXV:PCRX) entered into definitive share purchase agreement to acquire Eight PharmaChoice Canada bannered pharmacies in Eastern Canada from two unnamed vendor groups for approximately CAD 24.2 million on April 28, 2026. A cash consideration of CAD 24.2 million will be paid by PharmaCorp Rx Inc. subject to customary adjustments. As part of consideration, CAD 24.2 million is paid towards interests of Eight PharmaChoice Canada bannered pharmacies in Eastern Canada. The consideration is expected to be funded using the Corporation’s existing cash resources. In addition, the Corporation has also entered into non-binding letters of intent (“LOIs”) in respect of four additional pharmacy acquisitions. All locations will continue to be operated by their existing managing pharmacists, ensuring continuity of care, preserving patient relationships, and supporting a seamless transition and integration into the PharmaCorp platform. The transaction is subject to customary closing conditions. The Transaction is expected to close within 60 days. PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Eight PharmaChoice Canada bannered pharmacies in Eastern Canada from two unnamed vendor groups for approximately CAD 24.2 million on July 6, 2026.
Reported Earnings • May 05Full year 2025 earnings released: CA$0.012 loss per share (vs CA$0.012 loss in FY 2024)Full year 2025 results: CA$0.012 loss per share (in line with FY 2024). Revenue: CA$20.9m (up 261% from FY 2024). Net loss: CA$1.48m (loss widened 46% from FY 2024). Revenue is forecast to grow 61% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Consumer Retailing industry in Canada. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Nov 30Third quarter 2025 earnings released: CA$0.004 loss per share (vs CA$0.009 loss in 3Q 2024)Third quarter 2025 results: CA$0.004 loss per share (improved from CA$0.009 loss in 3Q 2024). Revenue: CA$4.80m (up 335% from 3Q 2024). Net loss: CA$427.5k (loss narrowed 56% from 3Q 2024).
お知らせ • Nov 29PharmaCorp Rx Inc. Announces Management ChangesPharma Corp. Rx Inc. announced an executive transition in which Paul Dale has been appointed President and Chief Operating Officer, effective December 1, 2025, as Calvin LeRoux steps aside from the President role and assumes a one-year appointment as Strategic Advisor to the Chief Executive Officer. Mr. Dale has served as PharmaCorp’s Chief Operating Officer since its inception and will now take on broader leadership responsibilities as PharmaCorp advances its national expansion strategy. Mr. LeRoux will conclude his term as President on November 30, 2025. In his new advisory role, he will assist with the transition of responsibilities, contribute to strategic initiatives, and continue providing guidance on matters relating to PharmaChoice Canada. The company also pleased to announce that Sophia Sigler will join the Corporation as Director, Business Development, effective December 1, 2025. Ms. Sigler will lead the PharmaCorp’s business development initiatives, including sourcing acquisition opportunities, managing the transaction pipeline, coordinating due diligence, and supporting pharmacist partners through co-ownership and succession structures.
New Risk • Nov 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 35% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CA$66.8m market cap, or US$47.5m).
Buy Or Sell Opportunity • Nov 21Now 24% overvaluedOver the last 90 days, the stock has fallen 10% to CA$0.43. The fair value is estimated to be CA$0.35, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 156% over the last 3 years. Earnings per share has grown by 43%.
お知らせ • 3hPharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Eight PharmaChoice Canada bannered pharmacies in Eastern Canada from two unnamed vendor groups for approximately CAD 24.2 million.PharmaCorp Rx Inc. (TSXV:PCRX) entered into definitive share purchase agreement to acquire Eight PharmaChoice Canada bannered pharmacies in Eastern Canada from two unnamed vendor groups for approximately CAD 24.2 million on April 28, 2026. A cash consideration of CAD 24.2 million will be paid by PharmaCorp Rx Inc. subject to customary adjustments. As part of consideration, CAD 24.2 million is paid towards interests of Eight PharmaChoice Canada bannered pharmacies in Eastern Canada. The consideration is expected to be funded using the Corporation’s existing cash resources. In addition, the Corporation has also entered into non-binding letters of intent (“LOIs”) in respect of four additional pharmacy acquisitions. All locations will continue to be operated by their existing managing pharmacists, ensuring continuity of care, preserving patient relationships, and supporting a seamless transition and integration into the PharmaCorp platform. The transaction is subject to customary closing conditions. The Transaction is expected to close within 60 days. PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Eight PharmaChoice Canada bannered pharmacies in Eastern Canada from two unnamed vendor groups for approximately CAD 24.2 million on July 6, 2026.
Reported Earnings • May 05Full year 2025 earnings released: CA$0.012 loss per share (vs CA$0.012 loss in FY 2024)Full year 2025 results: CA$0.012 loss per share (in line with FY 2024). Revenue: CA$20.9m (up 261% from FY 2024). Net loss: CA$1.48m (loss widened 46% from FY 2024). Revenue is forecast to grow 61% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Consumer Retailing industry in Canada. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Nov 30Third quarter 2025 earnings released: CA$0.004 loss per share (vs CA$0.009 loss in 3Q 2024)Third quarter 2025 results: CA$0.004 loss per share (improved from CA$0.009 loss in 3Q 2024). Revenue: CA$4.80m (up 335% from 3Q 2024). Net loss: CA$427.5k (loss narrowed 56% from 3Q 2024).
お知らせ • Nov 29PharmaCorp Rx Inc. Announces Management ChangesPharma Corp. Rx Inc. announced an executive transition in which Paul Dale has been appointed President and Chief Operating Officer, effective December 1, 2025, as Calvin LeRoux steps aside from the President role and assumes a one-year appointment as Strategic Advisor to the Chief Executive Officer. Mr. Dale has served as PharmaCorp’s Chief Operating Officer since its inception and will now take on broader leadership responsibilities as PharmaCorp advances its national expansion strategy. Mr. LeRoux will conclude his term as President on November 30, 2025. In his new advisory role, he will assist with the transition of responsibilities, contribute to strategic initiatives, and continue providing guidance on matters relating to PharmaChoice Canada. The company also pleased to announce that Sophia Sigler will join the Corporation as Director, Business Development, effective December 1, 2025. Ms. Sigler will lead the PharmaCorp’s business development initiatives, including sourcing acquisition opportunities, managing the transaction pipeline, coordinating due diligence, and supporting pharmacist partners through co-ownership and succession structures.
New Risk • Nov 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 35% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CA$66.8m market cap, or US$47.5m).
Buy Or Sell Opportunity • Nov 21Now 24% overvaluedOver the last 90 days, the stock has fallen 10% to CA$0.43. The fair value is estimated to be CA$0.35, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 156% over the last 3 years. Earnings per share has grown by 43%.
Recent Insider Transactions • Nov 16Executive Chairperson recently bought CA$1.0m worth of stockOn the 12th of November, Alan Simpson bought around 2m shares on-market at roughly CA$0.42 per share. This transaction amounted to 32% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Alan's only on-market trade for the last 12 months.
お知らせ • Nov 13PharmaCorp Rx Inc. has completed a Composite Units Offering in the amount of CAD 23.0391 million.PharmaCorp Rx Inc. has completed a Composite Units Offering in the amount of CAD 23.0391 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 47,700,000 Price\Range: CAD 0.42 Discount Per Security: CAD 0.0252
お知らせ • Aug 25PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2025PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2025.
Reported Earnings • Aug 18Second quarter 2025 earnings released: CA$0.003 loss per share (vs CA$0.011 loss in 2Q 2024)Second quarter 2025 results: CA$0.003 loss per share (improved from CA$0.011 loss in 2Q 2024). Revenue: CA$4.40m (up CA$4.10m from 2Q 2024). Net loss: CA$384.1k (loss narrowed 36% from 2Q 2024).
お知らせ • Aug 08PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business from PharmaChoice Canada Inc.PharmaCorp Rx Inc. (TSXV:PCRX) entered into share purchase agreement to acquire Pharmacy business from PharmaChoice Canada Inc. for CAD 2.4 million on June 24, 2025. The purchase price is subject to customary adjustments which will be paid using cash on hand. The Acquisition is expected to close on or about July 31, 2025, subject to satisfaction of customary closing conditions. PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business from PharmaChoice Canada Inc on August 7, 2025.
Buy Or Sell Opportunity • Jul 30Now 24% overvaluedOver the last 90 days, the stock has fallen 4.1% to CA$0.47. The fair value is estimated to be CA$0.38, however this is not to be taken as a sell recommendation but rather should be used as a guide only.
分析記事 • Jul 28Calculating The Fair Value Of PharmaCorp Rx Inc. (CVE:PCRX)Key Insights PharmaCorp Rx's estimated fair value is CA$0.38 based on 2 Stage Free Cash Flow to Equity With CA$0.46...
Buy Or Sell Opportunity • Jul 08Now 29% overvalued after recent price riseOver the last 90 days, the stock has risen 2.1% to CA$0.49. The fair value is estimated to be CA$0.38, however this is not to be taken as a sell recommendation but rather should be used as a guide only.
Buy Or Sell Opportunity • Jun 04Now 24% overvaluedOver the last 90 days, the stock has fallen 9.8% to CA$0.46. The fair value is estimated to be CA$0.37, however this is not to be taken as a sell recommendation but rather should be used as a guide only.
New Risk • Feb 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (478% increase in shares outstanding). Revenue is less than US$1m (CA$1.4m revenue, or US$981k). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (CA$64.5m market cap, or US$45.3m).
Board Change • Oct 04High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Ken Brownell was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 03PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business including land and buildings located in Atlanfic Canada.PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire Pharmacy business including land and buildings located in Atlanfic Canada for CAD 15.4 million on September 24, 2024. A cash consideration of CAD 15.18 million will be paid by PharmaCorp Rx Inc. The consideration consists of common equity of PharmaCorp Rx Inc. having a value of CAD 0.2 million to be issued for assets of Pharmacy business including land and buildings located in Atlanfic Canada. As part of consideration, CAD 15.38 million is paid towards assets of Pharmacy business including land and buildings located in Atlanfic Canada. For the period ending April 30, 2024, Pharmacy business including land and buildings located in Atlanfic Canada reported total revenue of CAD 10.36 million, net income of CAD 0.44 million, net assets of CAD 2.21 million and total debt of CAD 1.01 million. The transaction is subject to satisfaction of customary closing conditions, including the conditional acceptance of the TSX Venture Exchange. The expected completion of the transaction is October 1, 2024. PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business including land and buildings located in Atlanfic Canada on October 2, 2024.
お知らせ • Sep 05PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of 90% stake in Pharmacy Located in Western Canada.PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire 90% stake in Pharmacy Located in Western Canada for CAD 2.2 million on August 22, 2024. The consideration will be funded from cash. A key aspect of the transaction is that the Vendors will retain a 10% interest in the Acquired Pharmacy and have agreed to continue working at the Acquired Pharmacy, with one of the Vendors entering into a long-term employment agreement as the managing pharmacist. The transaction is subject to satisfaction of customary closing conditions. The expected completion of the transaction is August 30, 2024. PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of 90% stake in Pharmacy Located in Western Canada on September 3, 2024.
お知らせ • Aug 23PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire 90% stake in Pharmacy Located in Western Canada for CAD 2.2 million.PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire 90% stake in Pharmacy Located in Western Canada for CAD 2.2 million on August 22, 2024. The consideration will be funded from cash. A key aspect of the transacfion is that the Vendors will retain a 10% interest in the Acquired Pharmacy, and have agreed to confinue working at the Acquired Pharmacy, with one of the Vendors entering into a long-term employment agreement as the managing pharmacist. The transaction is subject to satisfaction of customary closing conditions. The expected completion of the transaction is August 30, 2024.
お知らせ • Aug 22PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2024PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2024.
New Risk • Aug 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 366% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Shareholders have been substantially diluted in the past year (366% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (CA$43.8m market cap, or US$31.6m).
Board Change • Jul 23High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Director Glenn Fradette is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 08+ 1 more updateProton Capital Corp. has completed a Follow-on Equity Offering in the amount of CAD 20.797658 million.Proton Capital Corp. has completed a Follow-on Equity Offering in the amount of CAD 20.797658 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 51,994,146 Price\Range: CAD 0.4
お知らせ • May 29Proton Capital Corp. (TSXV:PTN.P) agreed to acquire 75%stake in Saskatoon Family Pharmacy.Proton Capital Corp. (TSXV:PTN.P) agreed to acquire 75%stake in Saskatoon Family Pharmacy on May 27, 2024.
お知らせ • Nov 17Proton Capital Corp., Annual General Meeting, Jan 22, 2024Proton Capital Corp., Annual General Meeting, Jan 22, 2024.
